Roche’s Alecensa® (alectinib) Receives CFDA Priority Review for 1L ALK +ve mNSCLC

 Roche’s Alecensa® (alectinib) Receives CFDA Priority Review for 1L ALK +ve mNSCLC

Roche’s Hemlibra P-III Positive results for Haemophilia A without factor VIII being published in NEJM

Shots:
  • Alecensa approval in china is after 8 & 9 mos post EMA and US FDA approvals, Alecensa is now approved in over 57 countries
  • The approval is based on the pivotal Ph III studies ALEX and ALESIA assessing Alecensa vs crizotinib, and two Ph II assessing Alecensa in patients on or are intolerant to crizotinib
  • ALEX results: mPFS (27.7mos vs 7.4mos); ORR (82.9% vs 75.5%); Death reduced to 53%

Click here to read full press release/ article | Ref: Roche | Image:  ASLM

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post